Bajaj Finserv Healthcare Fund
Direct · GrowthAI Summary
The fund's 1Y SIP XIRR of 16.17% comfortably exceeds the category average of 10.69%, indicating strong recent SIP performance. Against the NIFTY 50, the fund posted a 1Y CAGR of 11.79% versus the benchmark's -11.43%, generating a notable alpha of 15.09%. However, over longer horizons (7Y-15Y), alpha turns negative, suggesting recent outperformance may not be sustained over full market cycles.
The fund exhibits low beta of 0.55-0.63 versus NIFTY 50, with downside capture of 41.69% (1Y) and 60.54% (3Y), meaning it has historically fallen significantly less than the benchmark in weak markets. The maximum drawdown of just -0.16% with a 57-day duration and 262-day recovery indicates shallow recent drawdowns, though 2 drawdown events exceeding 10% show deeper losses have occurred historically. The 1Y Calmar ratio of 0.75 reflects reasonable risk-adjusted returns over the past year.
The portfolio is heavily concentrated in Pharmaceuticals & Biotechnology at 62.4% of NAV, with Healthcare Services adding another 17.0%, making it a near-pure healthcare play. Divi's Laboratories (10.55%) and Sun Pharmaceutical (8.21%) are the largest positions, and the top 10 holdings account for roughly 57% of the 31-stock portfolio. Hospital operators (Apollo, Max, Fortis) provide some diversification within the healthcare theme.
The fund's 1Y SIP XIRR of 16.17% outpaces the sectoral/thematic category average of 10.69% by a wide margin. Calendar year returns have been uneven, however, with -2.96% in 2025 and just 0.18% in 2024 before a strong 14.84% in 2026, indicating performance is highly dependent on healthcare sector cycles. As a relatively newer fund, it lacks a long-term track record to validate consistency across full market cycles.
This fund suits investors with high risk tolerance who already hold diversified core equity funds and want a tactical healthcare sector allocation. Given the sector concentration and uneven calendar-year returns, a horizon of at least 5-7 years is advisable to ride through sector downcycles. It should be treated as a satellite holding, typically limited to 5-10% of an overall equity portfolio.
- 1Y SIP XIRR of 16.17% significantly outperforms the category average of 10.69%
- Low beta of 0.55 with downside capture of only 41.69% over 1Y, offering strong downside resilience versus NIFTY 50
- Diversified within the healthcare theme across pharma, APIs, and hospital services with 31 holdings
- Extreme sector concentration with 79.4% in pharma and healthcare services exposes investors to single-sector risk
- Negative alpha over 7Y-15Y horizons (e.g., -1.14% over 10Y) suggests weak long-term risk-adjusted outperformance versus the benchmark
Generated on 21-10-2026, 3:04 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.63 L | 15.8% | -11.5% | 49.6% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 15.8% | 14.3% | 10.7% | +1.5% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 11.7% | 12.5% | -4.2% | 27.1% | 0.65 | 1.64 | 88% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +15.09 | 0.55 | 64.8% | 41.7% | 11.8% | -11.4% |
| 3 Years | +1.91 | 0.63 | 70.5% | 60.5% | 3.7% | -1.1% |
| 5 Years | +0.16 | 0.63 | 70.5% | 60.5% | 2.2% | -0.7% |
| 7 Years | -0.58 | 0.63 | 70.5% | 60.5% | 1.6% | -0.5% |
| 10 Years | -1.14 | 0.63 | 70.5% | 60.5% | 1.1% | -0.3% |
| 12 Years | -1.36 | 0.63 | 70.5% | 60.5% | 0.9% | -0.3% |
| 15 Years | -1.57 | 0.63 | 70.5% | 60.5% | 0.7% | -0.2% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Divi's Laboratories Limited | 10.55% |
| 2 | Sun Pharmaceutical Industries Limited | 8.21% |
| 3 | Rubicon Research Limited | 6.81% |
| 4 | Aurobindo Pharma Limited | 6.18% |
| 5 | Apollo Hospitals Enterprise Limited | 6.00% |
| 6 | Torrent Pharmaceuticals Limited | 5.03% |
| 7 | Neuland Laboratories Limited | 4.11% |
| 8 | Emcure Pharmaceuticals Limited | 3.84% |
| 9 | Max Healthcare Institute Limited | 3.35% |
| 10 | Fortis Healthcare Limited | 2.69% |